Syndax pharmaceuticals inc (SNDX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-56,981

-56,047

-60,884

-65,394

-68,865

-73,961

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-47,113

-

-38,920

-31,682

-29,538

-24,119

0

0

0

Adjustments to reconcile net loss to net cash from operating activities:
Depreciation

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization and accretion of investments

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash operating lease expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation, amortization and accretion

-

-

-

-

-

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Stock-based compensation

6,242

6,005

5,952

6,139

6,372

6,201

6,009

5,617

5,494

5,450

5,117

4,564

3,895

4,708

4,931

5,427

5,748

3,882

0

0

0

Change in fair value of warrants and derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Other

-

-

-

-

-

-11

1

2

-2

-8

0

0

0

-

-

-

-

-

-

-

-

Change in fair value of warrants and derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Changes in operating assets and liabilities:
Prepaid expenses and other assets

129

52

-3,755

-1,215

-1,202

-1,033

2,865

2,094

1,810

329

1,797

2,317

2,157

1,629

566

1,145

1,474

1,205

0

0

0

Accounts payable

4,651

4,739

3,453

-3,021

1,758

-792

960

2,073

-202

-194

159

1,777

1,692

923

1,173

641

64

1,045

0

0

0

Deferred revenue

-1,517

-1,517

-1,517

-1,517

-1,517

-1,517

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

-

-

-

-

-1,220

-

-1,220

-1,220

-932

16,660

0

0

0

Accrued expenses and other liabilities

-1,906

-3,411

-3,149

445

-3,854

974

1,461

5,634

6,123

5,305

4,966

3,257

3,550

4,842

3,168

937

1,467

-1,940

0

0

0

Net cash used in operating activities

-49,706

-50,612

-52,928

-62,868

-65,492

-68,531

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-41,422

-

-29,036

-22,770

-19,876

-2,428

0

0

0

Purchases of property and equipment

-

-

-

-

-

187

0

0

0

-

-

-

-

261

0

0

0

-

-

-

-

Change in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Purchases of short-term investments

118,328

104,018

87,595

104,589

87,789

78,844

99,392

98,423

149,865

152,263

139,579

136,376

93,537

158,319

165,038

169,902

159,307

102,008

0

0

0

Proceeds from sales and maturities of short-term investments

99,304

116,799

109,756

117,894

139,309

130,429

136,593

139,078

134,680

135,275

142,327

140,367

133,535

140,297

108,279

97,538

70,283

40,506

0

0

0

Net cash (used in) provided by investing activities

-19,024

12,781

22,147

13,291

51,506

51,398

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in initial public offering, net

-

-

-

-

-

-

-

-

-

-

-

-

-

52,148

0

0

0

-

-

-

-

Proceeds from debt agreement, net

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from Employee Stock Purchase Plan

219

182

194

173

191

198

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

39,771

-

-57,269

-72,732

-89,322

-61,669

0

0

0

Proceeds from stock option exercises

0

-

-

-

-

-

-

-

-

277

0

0

0

-

-

-

-

-

-

-

-

Principal payments on capital lease obligation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance of convertible preferred stock, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

87,323

0

0

0

Other

-

-

-

-

7

8

0

0

0

-

-3

-3

-4

-4

0

0

0

-

-

-

-

Net cash provided by financing activities

55,142

28,570

34,657

44,039

44,122

15,729

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

771

-

44,844

103,194

123,103

77,267

0

0

0

NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

-13,588

-9,261

3,876

-5,538

30,136

-1,404

5,974

9,216

5,623

11,279

0

0

0

-

-

-

-

-

-

-

-

NET INCREASE IN CASH AND CASH EQUIVALENTS

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-41,461

7,692

13,905

13,170

0

0

0

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

SUPPLEMENTAL DISCLOSURES OF NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance costs debt included in accounts payable and accrued expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Property and equipment purchases included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

Accretion of convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Accretion of dividends on convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

0

Issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

0

0

-

0

0

0

-

-

-

-

IPO issuance costs included in accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Vesting of restricted stock

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

Reclassification of common stock warrant liability to additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Conversion of preferred stock to common stock upon closing of initial public offering

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

At-the-Market Offering [Member]
Proceeds from issuance of common stock, net

-

830

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Private Placement [Member]
Proceeds from issuance of common stock, net

34,675

27,380

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-